Cellosaurus logo
expasy logo

Cellosaurus BHP2-7 Pazopanib selected (CVCL_4W01)

[Text][XML][JSON]
Cell line name BHP2-7 Pazopanib selected
Accession CVCL_4W01
Resource Identification Initiative To cite this cell line use: BHP2-7 Pazopanib selected (RRID:CVCL_4W01)
Comments Problematic cell line: Contaminated. Parent cell line (BHP 2-7) has been shown to be a TPC-1 derivative.
Population: Japanese.
Selected for resistance to: ChEBI; CHEBI_71219; Pazopanib (Votrient).
Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
Sequence variations
  • Gene fusion; HGNC; HGNC:18782; CCDC6 + HGNC; HGNC:9967; RET; Name(s)=CCDC6-RET, RET/PTC1 (from parent cell line).
  • Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Ala68fs (c.204_208delGGAGC); Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; HGNC:11355; STAG2; Simple; p.Gln1089Ter (c.3265C>T); Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (from parent cell line).
Disease Thyroid gland papillary carcinoma (NCIt: C4035)
Differentiated thyroid carcinoma (ORDO: Orphanet_146)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_6283 (BHP 2-7)
Sex of cell Female
Age at sampling Adult
Category Cancer cell line
Publications

PubMed=24628546; DOI=10.1210/jc.2013-2658; PMCID=PMC5393484
Crescent R. Isham, Brian C. Netzel, Ayoko R. Bossou, Dragana Milosevic, Kendall W. Cradic, Stefan K.G. Grebe, Keith C. Bible;
Development and characterization of a differentiated thyroid cancer cell line resistant to VEGFR-targeted kinase inhibitors.
J. Clin. Endocrinol. Metab. 99:E936-E943(2014)

Cross-references
Encyclopedic resources Wikidata; Q54796506
Entry history
Entry creation14-Dec-2015
Last entry update19-Dec-2024
Version number15